Peter F Rebeiro1, Cathy A Jenkins1, Aihua Bian1, Jordan E Lake2, Kassem Bourgi3, Richard D Moore4, Michael A Horberg5, W Christopher Matthews6, Michael J Silverberg7, Jennifer Thorne4, Angel M Mayor8, Viviane D Lima9, Frank J Palella10, Michael S Saag11, Keri N Althoff4, M John Gill12, Cherise Wong4, Marina B Klein13, Heidi M Crane14, Vincent C Marconi15, Bryan E Shepherd1, Timothy R Sterling1, John R Koethe1,16. 1. Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 2. University of Texas Health Science Center at Houston, Houston, Texas, USA. 3. Indiana University School of Medicine, Indianapolis, Indiana, USA. 4. Johns Hopkins University, Baltimore, Maryland, USA. 5. Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA. 6. University of California, San Diego, San Diego, California, USA. 7. Kaiser Permanente Northern California, Oakland, California, USA. 8. Retrovirus Research Center, Universidad Central del Caribe, Bayamón, Puerto Rico, USA. 9. University of British Columbia, Vancouver, British Columbia, Canada. 10. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 11. University of Alabama at Birmingham, Birmingham, Alabama, USA. 12. University of Calgary, Calgary, Alberta, Canada. 13. McGill University, Montreal, Quebec, Canada. 14. University of Washington, Seattle, Washington, USA. 15. Emory University School of Medicine, Atlanta, Georgia, USA. 16. Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
Abstract
BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) is associated with greater weight gain among persons with human immunodeficiency virus (HIV), though metabolic consequences, such as diabetes mellitus (DM), are unclear. We examined the impact of initial cART regimen and weight on incident DM in a large North American HIV cohort (NA-ACCORD). METHODS: cART-naive adults (≥18 years) initiating INSTI-, protease inhibitor (PI)-, or nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens from January 2007 through December 2017 who had weight measured 12 (±6) months after treatment initiation contributed time until clinical DM, virologic failure, cART regimen switch, administrative close, death, or loss to follow-up. Multivariable Cox regression yielded adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident DM by cART class. Mediation analyses, with 12-month weight as mediator, similarly adjusted for all covariates. RESULTS: Among 22 884 eligible individuals, 47% started NNRTI-, 30% PI-, and 23% INSTI-based cART with median follow-up of 3.0, 2.3, and 1.6 years, respectively. Overall, 722 (3%) developed DM. Persons starting INSTIs vs NNRTIs had incident DM risk (HR, 1.17 [95% CI, .92-1.48]), similar to PI vs NNRTI initiators (HR, 1.27 [95% CI, 1.07-1.51]). This effect was most pronounced for raltegravir (HR, 1.42 [95% CI, 1.06-1.91]) vs NNRTI initiators. The INSTI-DM association was attenuated (HR, 1.03 [95% CI, .71-1.49] vs NNRTIs) when accounting for 12-month weight. CONCLUSIONS: Initiating first cART regimens with INSTIs or PIs vs NNRTIs may confer greater risk of DM, likely mediated through weight gain.
BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) is associated with greater weight gain among persons with human immunodeficiency virus (HIV), though metabolic consequences, such as diabetes mellitus (DM), are unclear. We examined the impact of initial cART regimen and weight on incident DM in a large North American HIV cohort (NA-ACCORD). METHODS: cART-naive adults (≥18 years) initiating INSTI-, protease inhibitor (PI)-, or nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens from January 2007 through December 2017 who had weight measured 12 (±6) months after treatment initiation contributed time until clinical DM, virologic failure, cART regimen switch, administrative close, death, or loss to follow-up. Multivariable Cox regression yielded adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident DM by cART class. Mediation analyses, with 12-month weight as mediator, similarly adjusted for all covariates. RESULTS: Among 22 884 eligible individuals, 47% started NNRTI-, 30% PI-, and 23% INSTI-based cART with median follow-up of 3.0, 2.3, and 1.6 years, respectively. Overall, 722 (3%) developed DM. Persons starting INSTIs vs NNRTIs had incident DM risk (HR, 1.17 [95% CI, .92-1.48]), similar to PI vs NNRTI initiators (HR, 1.27 [95% CI, 1.07-1.51]). This effect was most pronounced for raltegravir (HR, 1.42 [95% CI, 1.06-1.91]) vs NNRTI initiators. The INSTI-DM association was attenuated (HR, 1.03 [95% CI, .71-1.49] vs NNRTIs) when accounting for 12-month weight. CONCLUSIONS: Initiating first cART regimens with INSTIs or PIs vs NNRTIs may confer greater risk of DM, likely mediated through weight gain.
Authors: A C Achhra; A Mocroft; P Reiss; C Sabin; L Ryom; S de Wit; C J Smith; A d'Arminio Monforte; A Phillips; R Weber; J Lundgren; M G Law Journal: HIV Med Date: 2015-07-28 Impact factor: 3.180
Authors: John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; Amy C Justice; Janet P Tate; Kate Buchacz; Sonia Napravnik; Angel M Mayor; Michael A Horberg; Aaron J Blashill; Amanda Willig; C William Wester; Michael J Silverberg; John Gill; Jennifer E Thorne; Marina Klein; Joseph J Eron; Mari M Kitahata; Timothy R Sterling; Richard D Moore Journal: AIDS Res Hum Retroviruses Date: 2015-09-09 Impact factor: 2.205
Authors: J A McCutchan; J A Marquie-Beck; C A Fitzsimons; S L Letendre; R J Ellis; R K Heaton; T Wolfson; D Rosario; T J Alexander; C Marra; B M Ances; I Grant Journal: Neurology Date: 2012-02-14 Impact factor: 9.910
Authors: Laurence Slama; Frank J Palella; Alison G Abraham; Xiuhong Li; Corinne Vigouroux; Gilles Pialoux; Lawrence Kingsley; Jordan E Lake; Todd T Brown Journal: J Antimicrob Chemother Date: 2014-08-04 Impact factor: 5.790
Authors: Paul E Sax; Kristine M Erlandson; Jordan E Lake; Grace A Mccomsey; Chloe Orkin; Stefan Esser; Todd T Brown; Jürgen K Rockstroh; Xuelian Wei; Christoph C Carter; Lijie Zhong; Diana M Brainard; Kathleen Melbourne; Moupali Das; Hans-Jürgen Stellbrink; Frank A Post; Laura Waters; John R Koethe Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079
Authors: Gabriel Spieler; Andrew O Westfall; Dustin M Long; Andrea Cherrington; Greer A Burkholder; Nicholas Funderburg; James L Raper; Edgar T Overton; Amanda L Willig Journal: AIDS Date: 2022-08-10 Impact factor: 4.632
Authors: Bruno Emond; Carmine Rossi; Aurélie Côté-Sergent; Keith Dunn; Patrick Lefebvre; Marie-Hélène Lafeuille; Prina Donga Journal: J Health Econ Outcomes Res Date: 2021-06-14
Authors: Rachel N Goldberg; Alexandra T Kania; Sarah M Michienzi; Mahesh Patel; Melissa E Badowski Journal: J Int Assoc Provid AIDS Care Date: 2021 Jan-Dec
Authors: Juan Carlos Lopez-Alvarenga; Dora A Martinez; Alvaro Diaz-Badillo; Liza D Morales; Rector Arya; Christopher P Jenkinson; Joanne E Curran; Donna M Lehman; John Blangero; Ravindranath Duggirala; Srinivas Mummidi; Ruben D Martinez Journal: Front Med (Lausanne) Date: 2021-07-05